Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959983 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 346
- Enrollment target
NCT02959983 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 346 participants.
The verdict
NCT02959983, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 346 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.
Interventions
- DRUG Placebo
- DRUG Eluxadoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2016-10-25 |
| Est. Completion | 2018-01-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02959983
The ClinicalTrials.gov registry entry for NCT02959983 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02959983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02959983 about?
NCT02959983 is a clinical study titled "Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use". This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D...
What is the current status of trial NCT02959983?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 346 participants. The study started on 2016-10-25. Estimated completion is 2018-01-22.
What interventions are being tested in trial NCT02959983?
The interventions under investigation include: Placebo (DRUG), Eluxadoline (DRUG).
Who is sponsoring clinical trial NCT02959983?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.